Ratings Genus plc

Equities

GNS

GB0002074580

Real-time Estimate Cboe Europe Other stock markets 11:02:32 2024-05-22 am EDT			5-day change	1st Jan Change
1,871 ^GBX	-0.05%		-1.48%	-14.01%

May. 02	Genus Power Infrastructures Forms New Subsidiary for Smart Metering Project	MT
Apr. 30	Deutsche Bank Initiates Genus at Buy	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
With an expected P/E ratio at 44.77 and 27.48 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GENUS PLC	-14.01%	1.56B	B
MODERNA, INC.	+57.60%	55.07B	B-
IQVIA HOLDINGS INC.	-1.86%	41.79B	B
LONZA GROUP AG	+44.36%	40.22B	A
CELLTRION, INC.	-7.59%	28.17B	C
ICON PUBLIC LIMITED COMPANY	+12.17%	26.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.08%	18.93B	B
BIO-TECHNE CORPORATION	+7.10%	13.03B	B+
MEDPACE HOLDINGS, INC.	+28.80%	12.26B	C+
UNITED THERAPEUTICS CORPORATION	+26.13%	12.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes